Tenocyclidine

Tenocyclidine (also known as TCP) is a dissociative anesthetic drug with hallucinogenic effects. It is similar in effects to phencyclidine but is considerably more potent due to increased stimulation of the NMDA receptor.

History

Tenocyclidine was discovered in the 1950s during research into analogs of phencyclidine. It was found to be around 3-5 times more potent than PCP and was considered for medical use in humans due to its increased potency and lower dosage requirement, but its development was dropped due to the high incidence of dysphoria and psychosis-like side effects.

Pharmacology

Like other dissociatives, tenocyclidine acts as an NMDA receptor antagonist. However, unlike most dissociatives, it also acts as a Dopamine reuptake inhibitor, which may explain some of its stimulating effects.

Effects

The effects of tenocyclidine are similar to those of other dissociatives. Users may experience feelings of detachment or disconnection from their bodies and surroundings, as well as hallucinations. However, due to its potency, the risk of overdose and serious side effects is higher than with other dissociatives.

Legal status

Tenocyclidine is a Schedule I controlled substance in the United States, meaning it is illegal to manufacture, buy, possess, or distribute without a license from the Drug Enforcement Administration.

See also

• Phencyclidine
• Dissociative
• NMDA receptor antagonist

References

Tenocyclidine Resources
Latest articles Most recent articles Ongoing trials	Wikipedia